Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of an investigational
neuromuscular blocking agent called CW002 and to document its effects on healthy adult
volunteers. A neuromuscular blocking agent is a drug that temporarily prevents muscles from
moving. CW002 has not yet been approved by the Food and Drug Administration (FDA).
Usually, neuromuscular blocking agents are used together with other drugs that put people
completely "asleep". These drugs allow doctors to place a breathing tube in the airway, stop
muscles from moving during surgical operations, and allow ventilation (movement of air).
This research is being done because CW002 is expected to act quickly and to provide a muscle
block of intermediate (not too long, not too short) duration. The researchers would like to
test increasing doses of CW002 that can be given without causing severe side effects. If
shown to be both safe and effective, such a compound would be useful in surgical procedures
and could improve future anesthetic care.